6340 Sequence Drive
271 articles with DexCom
Dexcom Schedules Second Quarter 2021 Earnings Release and Conference Call for July 29, 2021 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2021 financial results after market close on Thursday, July 29, 2021.
Dexcom announced today featured research and data presentations that will headline the 81st Scientific Sessions of the American Diabetes Association (ADA) virtual conference held June 25-29, 2021.
Results of two new studies illustrate continued momentum for Dexcom CGM, including JAMA-published data on additional populations who can benefit from the technology
Saskatchewan Health to Cover Dexcom G6 Continuous Glucose Monitoring System for People with Diabetes under the age of 18
Dexcom, Inc., a leader in real-time continuous glucose monitoring, announced that people with diabetes under the age of 18 living in Saskatchewan may now receive provincial coverage for the Dexcom G6 CGM System through Saskatchewan Health.
DexCom, Inc. announced that management will present an update on Dexcom at the following upcoming investor conference
RAMQ Now Offers Provincial Coverage of The Dexcom G6 Continuous Glucose Monitoring System for People Living with Type 1 Diabetes in Quebec
Proven to improve glycemic control and can reduce the risk of costly long-term diabetes-related complications compared to fingerstick monitoring.
DexCom, Inc. reported its financial results as of and for the quarter ended March 31, 2021.
Dexcom G6 CGM System Approved for Back of Upper Arm Wear, Offering Adults with Diabetes Greater Freedom
Dexcom, Inc., a leader in real-time continuous glucose monitoring, announced the company has received Health Canada authorization for the Dexcom G6 CGM System to be worn on the back of the upper arm by adults 18 and older.
Exyte, world-renowned for the design and construction of high-tech facilities, has been awarded a fast-track project for Dexcom in Penang, Malaysia.
Dexcom Schedules First Quarter 2021 Earnings Release and Conference Call for April 29, 2021 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2021 financial results after market close on Thursday, April 29, 2021. Management will hold a conference call to review the company's first quarter 2021 performance starting at 4:30 p.m. (Eastern Time) on the same day.
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the promotion of Jereme Sylvain to the role of Executive Vice President and Chief Financial Officer.
DexCom, Inc. announced that management will present an update on the company at the following upcoming virtual investor conferences
Dexcom Ventures to identify and invest in transformational technologies to advance long-term growth
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2020.
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2020 and Provides Initial 2021 Outlook
DexCom, Inc., the leader in continuous glucose monitoring, reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2020 to meet or exceed $567 million, an increase of 23% over the fourth quarter of 2019.
DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 39 th annual J.P. Morgan Healthcare Conference on January 11, 2021. The live presentation, which will occur virtually, is scheduled to begin at approximately 11:40 AM EST and will be concurrently webcast. The link to the webcast will be available on the Dexcom IR
DexCom, Inc. (NASDAQ:DXCM) announced today that it will host an Investor Day on December 9, from 8:30 AM until approximately 11:30 AM Pacific Standard Time (11:30 AM – 2:30 PM Eastern). The event, which will be held virtually, will include presentations from Dexcom management and industry leaders highlighting the company’s market opportunities, business strategy, innovation efforts and long-term financial outlook. Dexcom
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2020. Third Quarter 2020 Financial Highlights: Revenue grew 26% versus the same quarter of the prior year to $500.9 million U.S. revenue growth of 29% and international revenue growth of 17% GAAP operating income of $94.1 million or 18.8% of revenue, an increase of 470 basis points comp
Companies will partner to promote Lyumjev, Lilly's new rapid-acting insulin, with Dexcom G6 Continuous Glucose Monitoring, highlighting the benefits of using each
Dexcom Schedules Third Quarter 2020 Earnings Release and Conference Call for October 27, 2020 at 4:30 p.m. Eastern Time.
DexCom, Inc. announced that it plans to release its third quarter 2020 financial results after market close on Tuesday, October 27, 2020.